Business
IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms
SOUTH SAN FRANCISCO, Calif., January 12, 2026--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio’s (Nasdaq: CABA) investigational CAR T cell therapy rese-cel (resecabtagene autoleucel) has received FDA clearance of an IND Amendment (INDa) to use Cellares’ Cell Shuttle™ and Cell Q™ platforms for manufacturing and QC release testing.
About this update from Cabaletta Bio, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/c6af8994d414c32f79e51d17e13e2142"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8jJ.3tCU43XSQ.JDymxXcw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c6af8994d414c32f79e51d17e13e2142","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/C_Cj9hH9aiHTSCoxJ_HErw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/c6af8994d414c32f79e51d17e13e2142","width":1024,"height":512}},"lazy":false},{"type":"text","content":"The first GMP cell therapy product ever manufactured for clinical use on the Cell Shuttle™ and released using Cell Q™, is expected to be infused into patients within Cabaletta’s RESET™ clinical trial program in the first half of 2026.","length":234,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., January 12, 2026--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio’s (Nasdaq: CABA) investigational CAR T cell therapy rese-cel (resecabtagene autoleucel) has received FDA clearance of an IND Amendment (INDa) to use Cellares’ Cell Shuttle™ and Cell Q™ platforms for manufacturing and QC release testing.","length":417,"tagName":"p"},{"type":"text","content":"The clearance allows for the clinical manufacturing and release of rese-cel using Cellares’ fully automated end-to-end manufacturing and high-throughput quality control platforms, with first patient dosing anticipated in the first half of 2026. This milestone marks the Cell Shuttle and Cell Q platforms’ first use to support an active clinical program.","length":353,"tagName":"p"},{"type":"text","content":""Autoimmune cell therapy programs operate at a fundamentally different scale of patient demand than oncology," said Fabian Gerlinghaus, Co-founder and Chief Executive Officer of Cellares. "Achieving scalability in these larger indications is a differentiated feature of the Cellares platform. FDA approval of Cabaletta’s IND Amendment reflects regulatory confidence in the Cell Shuttle and Cell Q platforms to deliver reliable...